We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.
Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ALTO/MARKETING LIMITED

Infusion Catheter Delivers Therapeutics to Cardiac Patients

By HospiMedica International staff writers
Posted on 31 Jul 2018
Print article
Image: A novel catheter infuses drugs into the heart (Photo courtesy of Cook Regentec).
Image: A novel catheter infuses drugs into the heart (Photo courtesy of Cook Regentec).
A novel catheter designed for retrograde coronary sinus infusion (RCSI) procedures imbues therapeutic agents directly into the heart.

The Cook Regentec (Indianapolis, IN, USA) Advance CS coronary sinus infusion catheter is intended for temporary occlusion of the coronary sinus for infusion of contrast media, drugs, and therapeutic agents, or possible introduction of devices into the coronary venous system. The device consists of a double lumen catheter with a balloon near its distal tip; each lumen is individual. The distal lumen extends the length of the catheter and is used for placement of wired guides and infusion. The balloon lumen is used to expand the balloon. Platinum/Iridium radiopaque markers are positioned on the shaft for placement under fluoroscopy.

To monitor therapeutic drug infusion flow rate and pressures, the proprietary Compass CT Disposable Pressure Transducer is used to continuously monitor physiological pressure, displaying measurements during the infusion process on an integrated digital display. The Compass CT transducer can measure pressures ranging from -199 to +999 mm Hg, with an accuracy of ±3% above 50 mm. The measurements are constant, with zero drift of ±1 mm Hg per 4 hours. Multiple readings can be performed throughout one procedure.

“Using the Advance CS Coronary Sinus Infusion Catheter, clinicians can deliver therapeutics, including cell and gene therapies, in an out-patient setting,” said Amit Patel, MD, MS, chief of cardiac surgery at the University of Miami Health System (FL, USA). “What we once performed on patients through invasive surgery can now be done in a minimally invasive procedure, lowering medical costs, increasing patient safety, and delivering the most effective biologics to treat each patient. In the evolution of gene and cell therapies, this is a revolutionary medical device for both clinicians and patients.”

Related Links:
Cook Regentec


Print article
Italray

Channels

Copyright © 2000-2018 Globetech Media. All rights reserved.